Schonfeld Strategic Advisors LLC I Mab Transaction History

Schonfeld Strategic Advisors LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$12.54 - $46.93 $53,044 - $198,513	-4,230 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$45.28 - $74.5 $5.86 Million - $9.65 Million	-129,500 Reduced 96.84%	4,230 $200,000
Q3 2021 Nov 16, 2021	BUY	$57.18 - $84.43 $6.55 Million - $9.68 Million	114,630 Added 600.16%	133,730 $9.69 Million
Q2 2021 Nov 16, 2021	SELL	$47.86 - $83.95 $155,401 - $272,585	-3,247 Reduced 14.53%	19,100 $1.6 Million
Q2 2021 Aug 16, 2021	SELL	$47.86 - $83.95 $2.29 Million - $4.02 Million	-47,904 Reduced 68.19%	22,347 $1.88 Million
Q1 2021 May 17, 2021	BUY	$44.38 - $63.97 $3.12 Million - $4.49 Million	70,251 New	70,251 $3.41 Million
Q2 2020 Aug 14, 2020	SELL	$13.0 - $31.0 $243,555 - $580,785	-18,735 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$10.63 - $15.37 $199,153 - $287,956	18,735 New	18,735 $244,000

15.5M

56.4K

5.8K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $78.9M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.